By constructing pro-TCEs that contain peptide masks tethered to the TAA binding site through cancer protease-cleavable linkers, several companies are testing masked TCEs against EGFR, HER2 and PSMA, TAAs that have not been amenable to safe TCE targeting in the past due to off-target or CRS toxicity (129). This evidence concerns the gene EGFR and cancer.